Diana Bernstein, Ph.D.

Diana Bernstein, Ph.D. has extensive work experience in the field of biotechnology and venture capital. Diana is currently serving as a Principal at Northpond Ventures since January 2023, after holding the position of Vice President from June 2021 to January 2023. In addition, Diana serves as a Board Director at CAMP4 Therapeutics, Torque Bio, Mestag Therapeutics, Code Biotherapeutics, and OMass Therapeutics, starting in December 2022. Diana also served as a Board Observer at Parthenon Therapeutics from August 2021.

Prior to their current roles, Diana worked at Merck as a Senior Associate in the MRL Ventures Fund from December 2018 to June 2021. Before joining Merck, they had various roles at Flagship Pioneering, including Associate from January 2017 to December 2018, Consultant from September 2016 to December 2016, and Fellow from June 2016 to August 2016.

Diana began their career as a PhD Candidate at the University of Pennsylvania, where they conducted research from September 2011 to December 2015.

Diana Bernstein, Ph.D., has an educational background that includes a Bachelor of Science (BS) degree in Finance, Cell Biology & Genetics from the University of Maryland. Diana obtained a PhD in Pharmacology from the University of Pennsylvania. The specific years of their education are not mentioned.